Lenalidomid Approved by FDA for Follicular and Marginal Zone Lymphoma
This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes. (Source: CancerNetwork)
Source: CancerNetwork - May 28, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news
Lenalidomide Approved by FDA for Follicular and Marginal Zone Lymphoma
This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes. (Source: CancerNetwork)
Source: CancerNetwork - May 28, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news
Newtown biopharm firm could reap $50M from Chinese licensing deal
Onconova Therapeutics Inc. could receive more than $50 million under a licensing deal it signed Monday for its lead experimental cancer therapy.
HanX Biopharmaceuticals acquired the rights in Greater China to rigosertib, a new drug candidate Bucks County-based Onconova is developing initially as a treatment for patients at higher risks for developing myelodysplastic syndromes of MDA. MDS is a type of cancer that can occur when the blood-fo rming cells in bone marrow become abnormal.
Under the… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 13, 2019 Category: Biotechnology Authors: John George Source Type: news
Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
BOSTON and STOCKHOLM, April 16, 2019 -- (Healthcare Sales & Marketing Network) -- Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announ... Biopharmaceuticals, Oncology, FDA Aprea Therapeutics, p53, myelodysplastic syndromes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 16, 2019 Category: Pharmaceuticals Source Type: news
Aprea Therapeutics Adds New Investor to Series C Financing
Janus Henderson Investors joins Investor Group
BOSTON and STOCKHOLM, Feb. 27, 2019 -- (Healthcare Sales & Marketing Network) -- Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor sup... Biopharmaceuticals, Oncology, Venture Capital Aprea Therapeutics, p53, myelodysplastic syndromes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 27, 2019 Category: Pharmaceuticals Source Type: news
Does Chemotherapy Increase the Risks of Myelodysplastic Syndrome and Acute Myeloid Leukemia?
The study, published in JAMA Oncology, examined whether treatment of 22 solid tumor types was associated with two therapy-related conditions. (Source: CancerNetwork)
Source: CancerNetwork - February 7, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Myelodysplastic Syndrome/AML Risk Increased After Chemo
Since 2000, risks for therapy - related myelodysplastic syndrome, AML up after chemo for solid cancers (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 4, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news
Myelodysplastic Syndrome/AML Risk Increased After Chemo
FRIDAY, Jan. 4, 2019 -- The risks for therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) are elevated after chemotherapy use for solid tumors, according to a study published online Dec. 20 in JAMA Oncology.
Lindsay M.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 4, 2019 Category: Pharmaceuticals Source Type: news
Study finds elevated risk of rare blood cancers after chemotherapy for most solid tumors
(NIH/National Cancer Institute) Findings from a new study by researchers at the National Cancer Institute (NCI) show that patients treated with chemotherapy for most solid tumors during 2000-2014 experienced an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML). The study was published December 20, 2018, in JAMA Oncology. NCI is part of the National Institutes of Health. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2018 Category: Cancer & Oncology Source Type: news
Identifying Molecular Markers of Relapse in Myelodysplastic Syndrome
In this month ' s installment ofAsk the PI,ONCOLOGY spoke with two authors of the study, Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists. (Source: CancerNetwork)
Source: CancerNetwork - December 17, 2018 Category: Cancer & Oncology Authors: Meagan A. Jacoby, MD, PhD, Matthew Walter, MD Source Type: news
Can Azacitidine Delay Relapse in MRD-Positive AML?
Azacitidine may delay or prevent relapse among patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news
Model Improves Predictions of Myelodysplastic Syndrome Prognosis Model Improves Predictions of Myelodysplastic Syndrome Prognosis
For patients with myelodyplastic syndrome, a machine-learning model provides a look into the future and can predict outcomes for each individual.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Luspatercept Reduces Blood Transfusions in MDS and Beta-Thalassemia Luspatercept Reduces Blood Transfusions in MDS and Beta-Thalassemia
A novel agent reduced the need for blood transfusions in two separate patient populations: myelodysplastic syndromes (MDS) and beta-thalassemia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Cleveland Clinic's Aziz Nazha, M.D., develops personalized prediction model for patients with MDS
(Cleveland Clinic) At the American Society of Hematology (ASH) Annual Meeting, Cleveland Clinic medical hematologist and oncologist Aziz Nazha, M.D., will present results of a personalized prediction model that surpassed current prediction models for Myelodysplastic Syndromes (MDS). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2018 Category: Cancer & Oncology Source Type: news
Lixte Biotechnology Files an IND with the FDA to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center
EAST SETAUKET, NY , Oct. 09, 2018 -- (Healthcare Sales & Marketing Network) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has submitted an IND to the FDA to conduct a Phase 1b/2 trial of the safety and therapeutic benefit of Lixtes... Biopharmaceuticals, Oncology, FDA Lixte Biotechnology, protein phosphatases, Myelodysplastic Syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 9, 2018 Category: Pharmaceuticals Source Type: news
